Saratov JOURNAL of Medical and Scientific Research
Home

Possible laboratory and instrumental markers of Parkinson's disease

Year: 2020, volume 16 Issue: №1 Pages: 336-341
Heading: Neurology Article type: Original article
Authors: Goncharova Z.A., Kolmakova T.S., Oksenyuk O.S., Morgul E.V., Gelpey M.A., Vlasova N.D., Smirnova O.B., Mutalieva Kh.M.
Organization:
Summary:

Objective: to evaluate the role of a complex of markers of inflammatory processes and free radical oxidation, an immunoreactivity profile, stabilographic indicators in the pathogenesis of Parkinson's disease (PD) for possible use as clinically significant markers of early diagnosis of the disease. Material and Methods. 139 patients with PD, 31 patients as the control, and 11 patients as the comparison with Parkinson's syndrome were examined. The following parameters were evaluated in blood serum: antidodies to NF-200, GFAP, S100, MBP, voltage-dependent-Ca-chan-nel, Na-Choline, glutamate, dopamine, serotonin, Mu-Opiate, GABA receptors, (3-Endorphin; total antioxidant activity; malondialdehyde's accumulation; determination of small, medium, large and giant circulating immune complexes and medium-weight molecules. Postural functions were evaluated using a biofeedback computer stabilizer. Results. Significant differences in the profiles of immunoreactivity, neuroinflammation and endogenous intoxication in patients and in the control group were revealed. The stabilometric indicator of the quality of the equilibrium function significantly varied depending on the stage of PD. Conclusion. The results indicate a possible role of activation of the immune system and neuroinflammation in the process of neurodegeneration in PD. The autoimmune response is specific in nature, progressively changing depending on the stage of the disease.

Keywords: autoimmune disorders, early diagnosis, Parkinson disease, stabilometrics

Bibliography:
1. Lee A, Gilbert RM. Epidemiology of Parkinson Disease. Neurol Clin 2016 Nov; 34 (4): 955-65.
2. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30: 1591-601.
2. Caggiu E, Arm G, Hosseini S, et al. Inflammation, Infectious Triggers, and Parkinson's Disease. Front Neurol 2019 Febr; 10: 122.
3. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988 Aug;38(8): 1285-91.
4. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; (60): 1059-64.
5. Caggiu E, Paulus K,Arru G, etal. Humoral cross reactivity between a-synuclein and Herpes simplex-1 epitopein Parkinson's disease, a triggering role in the disease? J Neuroimmunol 2016; (291): 110-4.
6. Matheoud D, Sugiura A, Bellemare-Pelletier A, et al. Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. Cell 2016; 166: 314-27.
7. Liebner S, Dijkhuizen RM, Reiss Y, et al. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol 2018; 135: 311-36.
8. Goncharova ZA, Kolmakova TS, Oxenyuk OS, et al. Multiparameter assessment of biochemical blood markers in Parkinson's disease. Practical Medicine 2018; 10: 87-91.
9. DeKosky ST, Marek К. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003; (302): 830-4.
10. Gao HM, Jiang J, Wilson B, et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002; 81 (6): 1285-97.
11.Garret.ti F, Agalliu D, Lindestam Arlehamn CS, et al. Autoimmunity in Parkinson' Disease: The Role of a-Synuclein-Specific T Cells. Frontiers in Immunology 2019 Febr; 10: 303.
12. RacetteBA, GrossA, VouriSM,etal.lmmunosuppressants and risk of Parkinson disease. Annals of Clinical andTranslational Neurology 2018; 5 (7): 870-5.
13. Goncharova ZA, Rabadanova EA, Gelpey MA. Epidemiological analysis of Parkinson's disease in Rostov-on-Don. Saratov Journal of Medical Scientific Research 2017; 13 (1): 135-9.
14. Goryacheva NV, Bulava GV, Vetoshkin Al, Godkov MA. Modification of the determination of circulating immune complexes of various sizes in human serum. Clinical Laboratory Diagnostics 1997; (5): 77-8.
15. Gabrielyan Nl, Lipatova VI. The experience of using the average of molecules in the blood to diagnose nephrological diseases in children. Laboratory Work 1984; (3): 138-40.
16. Arutyunyan AV, Dubinina ЕЕ, Zybina NN. Methods for assessing free radical oxidation and the antioxidant system of the body: Guidelines. St. Petersburg: Foliant, 2000; 104 p.
17. Sliva AS, Voynov ID, Sliva SS. The development of methods and means of computer stabilization. News of the Southern Federal University. Technical science 2010; 110 (9): 158-64.
18. Han М, Nagele Е, DeMarshall С, et al. Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera. PLoS ONE 2012; 7 (2): 32-8.
19. Potryasova AN, Baziyan BKh, lllarioshkin SN. Comprehensive assessment of postural instability in patients with early stages of Parkinson's disease. Nervous Diseases 2018; (2): 12-6.

AttachmentSize
2020_01-3_336-341.pdf347.25 KB
All articles of the authors: Goncharova Z.A. , Kolmakova T.S. , Morgul E.V. , Mutalieva Kh.M., Okseniuk O.S. , Smirnova O.B., Vlasova N.D.

No votes yet